Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2012, Article ID 517424, 2 pages
http://dx.doi.org/10.1155/2012/517424
Case Report

Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient

Rheumatology Unit, Valle del Lili Foundation, ICESI University, Cali, Colombia

Received 31 October 2012; Accepted 28 November 2012

Academic Editors: J. Mikdashi, P. Njobvu, and P. E. Prete

Copyright © 2012 J. H. Izquierdo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011. View at Google Scholar
  2. M. Feldmann and R. N. Maini, “Anti-TNFα therapy of rheumatoid arthritis: what have we learned?” Annual Review of Immunology, vol. 19, pp. 163–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Venkiteshwaran, “Tocilizumab,” MAbs, vol. 1, no. 5, pp. 432–438, 2009. View at Google Scholar · View at Scopus
  4. N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and J. Azuma, “Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1580–1584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Buch, “Sequential use of biologic therapy in rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 321–329, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Smolen, R. Landewé, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 964–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Singh, B. Saba, and M. A. Lopez-Olivo, “Tocilizumab for rheumatoid arthritis: a cochrane systematic review,” Journal of Rheumatology, vol. 38, no. 1, pp. 10–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Stern, “Exanthematous drug eruptions,” New England Journal of Medicine, vol. 366, no. 26, pp. 2492–2501, 2012. View at Publisher · View at Google Scholar